SCHEMBL2494083

SCHEMBL2494083

Oc1ccccc1/C=N/c1ccc(/N=C/c2ccccc2O)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SIRT2 Q8IXJ6 1/20 1.00
CA2 P00918 8/20 0.71
CA12 O43570 7/20 0.71
CA9 Q16790 7/20 0.71
CA1 P00915 2/20 0.71
MAOB P27338 3/20 0.63
TSHR P16473 1/20 0.61
KDM4E B2RXH2 1/20 0.57
LMNA P02545 1/20 0.56
GAA P10253 1/20 0.56
MAPT P10636 1/20 0.56
RAD52 P43351 1/20 0.56
CA7 P43166 1/20 0.53
PABPC1 P11940 1/20 0.53
APOBEC3A P31941 1/20 0.53
APOBEC3G Q9HC16 1/20 0.53
MAOA P21397 1/20 0.51
CTRC Q99895 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2494084 1.00 SIRT2 (1.00) SIRT2CA2CA12CA9CA1
SCHEMBL30301787 0.94 SIRT2 (0.88) SIRT2CA2CA12CA9CA1
SCHEMBL10620536 0.94 SIRT2 (0.88) SIRT2CA2CA12CA9CA1
SCHEMBL10620538 0.94 SIRT2 (0.88) SIRT2CA2CA12CA9CA1
2-((Phenylimino)Methyl)Phenol SCHEMBL347862 0.93 SIRT2 (0.88) SIRT2CA2CA12CA9CA1
2-((Phenylimino)Methyl)Phenol SCHEMBL29424118 0.93 SIRT2 (0.88) SIRT2CA2CA12CA9CA1
2-((Phenylimino)Methyl)Phenol SCHEMBL347861 0.93 SIRT2 (0.88) SIRT2CA2CA12CA9CA1
2-((Phenylimino)Methyl)Phenol SCHEMBL453634 0.91 SIRT2 (0.84) SIRT2CA2CA12CA9CA1
2-((Phenylimino)Methyl)Phenol SCHEMBL5418701 0.91 SIRT2 (0.84) SIRT2CA2CA12CA9CA1
2-((Phenylimino)Methyl)Phenol SCHEMBL27996307 0.91 SIRT2 (0.84) SIRT2CA2CA12CA9CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100256329-A1 STEREOSELECTIVE ALTERNATING COPOLYMERIZATION OF EPOXIDE WITH CARBON DIOXIDE THE UNIVERSITY OF TOKYO (JP) 2010-10-07 US claimed
EP-2014281-A1 Use of inhibitors of sirtuins and/or ampk for the preparation of a medicament for the treatment of polyalanine diseases. INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) 2009-01-14 EP claimed
WO-2008155390-A2 USE OF INHIBITORS OF SIRTUINS AND/OR AMPK FOR THE PREPARATION OF A MEDICAMENT FOR THE TREATMENT OF POLYALANINE DISEASES. INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) 2008-12-24 WO claimed
EP-1507837-B1 SEGMENTED CURABLE TRANSFER TAPES 3M INNOVATIVE PROPERTIES CO (US) 2008-01-09 EP claimed
EP-1507837-A1 SEGMENTED CURABLE TRANSFER TAPES 3M Innovative Properties Company (US) 2005-02-23 EP claimed
WO-2003102102-A1 SEGMENTED CURABLE TRANSFER TAPES 3M INNOVATIVE PROPERTIES COMPANY (US) 2003-12-11 WO claimed
US-20030221770-A1 Segmented curable transfer tapes 3M INNOVATIVE PROPERTIES COMPANY 2003-12-04 US claimed
US-9404001-B2 Photochromic latex ink XEROX CORPORATION (US) 2016-08-02 US disclosed
US-9404001-B2 Photochromic latex ink XEROX CORPORATION (US) 2016-08-02 US disclosed
US-20150192589-A1 METHOD USING FLUORESCENT TURN-ON PROBES FOR CELL-SPECIFIC DETECTION AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) 2015-07-09 US disclosed
US-20150192589-A1 METHOD USING FLUORESCENT TURN-ON PROBES FOR CELL-SPECIFIC DETECTION AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) 2015-07-09 US disclosed
US-20150153479-A1 PHOTOCHROMIC LATEX INK XEROX CORPORATION (US) 2015-06-04 US disclosed
US-20150153479-A1 PHOTOCHROMIC LATEX INK XEROX CORPORATION (US) 2015-06-04 US disclosed
US-7214456-B2 Reimageable medium XEROX CORPORATION (US) 2007-05-08 US disclosed
US-7205088-B2 Reimageable medium with light absorbing material XEROX CORPORATION (US) 2007-04-17 US disclosed
US-7205088-B2 Reimageable medium with light absorbing material XEROX CORPORATION (US) 2007-04-17 US disclosed
EP-1508261-A1 NANOPARTICLE FILLED UNDERFILL 3M Innovative Properties Company (US) 2005-02-23 EP disclosed
WO-2003101164-A1 NANOPARTICLE FILLED UNDERFILL 3M INNOVATIVE PROPERTIES COMPANY (US) 2003-12-04 WO disclosed
US-20030221770-A1 Segmented curable transfer tapes 3M INNOVATIVE PROPERTIES COMPANY 2003-12-04 US disclosed
US-20030218258-A1 Nanoparticle filled underfill 3M INNOVATIVE PROPERTIES COMPANY 2003-11-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100256329-A1 STEREOSELECTIVE ALTERNATING COPOLYMERIZATION OF EPOXIDE WITH CARBON DIOXIDE PCNA, HPD, TET3 SIRT2 2670/4885CA2 109/4885CA12 23/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.